



WST91BUS
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of) Group Art Unit: 1653
)
L. Otvos) Examiner:
)
Appln. No. 09/980,804)
)
Filed: December 3, 2001)
)
For: NOVEL PYRRHOCORICIN-DERIVED) August 19, 2003
PEPTIDES, AND METHODS OF USE)
THEREOF)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope address to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 19, 2003

Diana M. Waligun
Signature

Date

Diana M. Waligun

Typed or printed



PTO/SB/08B (04-03)

Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/980,804
Filing Date	12/03/2001
First Named Inventor	L. Otvos
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	WST91BUSA

Sheet 1 of 3

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	AAS	L. OTVOS, et al., "Antibacterial insect glycopeptides: Synthesis, structure and activity", <i>In: Peptides: Frontiers in Peptide Science</i> (J.P. Tam and P.T.P. Kaumaya, ed.) Kluwer, Dordrecht, The Netherlands, pp. 703-704 (January 1999)	
	AAT	M. CUDIC, et al., "Fully solid-phase synthesis and anti-microbial properties of a cyclic analog of pyrrhocoricin", <i>In: Peptides 2000</i> (J. Martinez, J.A.Fehrentz, eds.) EDK, Paris pp. 203-204 (2001)	
	AAU	L. OTVOS, et al., "In vivo active antibacterial peptides and their bacterial target proteins", <i>In: Peptides 2000</i> (J. Martinez, J.A.Fehrentz, eds.) EDK, Paris pp. 115-116 (2001)	
	AAV	M. CUDIC, et al., "Antibacterial activity spectrum of designed pyrrhocoricin analogs", <i>In Peptides: The Wave of the Future</i> (R.A. Houghten and M. Lebl, eds.), American Peptide Society, San Diego, pp. 493-494 (2001)	
	AAW	L. OTVOS, et al., "The proline-rich antibacterial peptide family inhibits chaperone-assisted protein folding", <i>In Peptides: The Wave of the Future</i> (R.A. Houghten and M. Lebl, eds.), American Peptide Society, San Diego, pp. 873-875 (2001)	
	AAX	M. CUDIC, et al., "Derivatives of the native antibacterial peptide pyrrhocoricin exhibit desirable pharmacological properties in vitro and in vivo", <i>In: Peptides 2002</i> (E. Benedetti and C. Pedone, eds), Edizioni Ziino, Napoli, pp. 452-453 (2002)	
	AAZ	L. OTVOS, et al., "Multifunctional antibacterial peptides", <i>In: Peptides 2002</i> (E. Benedetti and C. Pedone, eds), Edizioni Ziino, Napoli, pp. 580-581 (2002)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (04-03)
Approved for use through 4/30/2003. OMB 0651-0011
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

Sheet	2	of	3	Application Number	09/980,804
				Filing Date	12/03/2001
				First Named Inventor	L. Otvos
				Group Art Unit	1653
				Examiner Name	
				Attorney Docket Number	WST91BUSA

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
-	AAZ	L. OTVOS, "Antibacterial peptides isolated from insects", <i>J. Pept. Sci.</i> 6:497-511 (October 6, 2000)	
	BR	M. CUDIC, et al., "Intracellular targets of antibacterial peptides", <i>Curr. Drug Targets</i> 3(2):101-106 (April 2002)	
	BS	L. OTVOS, "The short, proline-rich antibacterial peptide family", <i>Cell. Mol. Life Sci.</i> , 59:1138-1150 (July 2002)	
	BT	P. BULET, et al., "Enlarged scale chemical synthesis and range of activity of drosocin, an O-glycosylated antibacterial peptide of <i>Drosophila</i> ", <i>Eur. J. Biochem.</i> 238:64-69 (May 15, 1996)	
	BU	R. HOFFMAN, et al., "Serum stability of phosphopeptides", <i>Anal. Chim. Acta</i> 352:319-325 (1997)	
	BV	M. CUDIC, et al., "Chemical synthesis, antibacterial activity and conformation of diptericin, an 82-mer peptide originally isolated from insects", <i>Eur. J. Biochem.</i> 266:549-558 (December 1999)	
	BW	L. OTVOS, et al., "Insect peptides with improved protease-resistance protect mice against bacterial infection", <i>Protein Sci.</i> 9:742-749 (April 2000)	
	BX	G. KRAGOL, et al., "The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding", <i>Biochemistry</i> 40:3016-3026 (March 13, 2001)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/58/088 (04-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known

Application Number	09/980,804
Filing Date	12/03/2001
First Named Inventor	L. Otvos
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	WST91BUSA

Sheet 3 of 3

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	BY	A.M. BENCIVENGO, et al., "The efficacy of the antibacterial peptide, pyrrocoricin, is finely regulated by its amino acid residues and active domains", <i>Lett. Pept. Sci.</i> 8: 201-209 (2002)	
	BZ	G. KRAGOL, et. al., "Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrocoricin", <i>Eur. J. Biochem.</i> 269: 4226-4237 (September 2002)	
	BBR	M. CUDIC, et al., "Development of novel antibacterial peptides that kill resistant clinical isolates", <i>In: Peptides</i> 23: 2071-2083 (December 2002)	
	BBS	M. CUDIC, et al., "In vitro and in vivo activity of an antibacterial peptide analog against uropathogens", <i>In: Peptides</i> , in press. (2003)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.